Form 4: Vir Biotechnology EVP Vanina de Verneuil Reports Stock Sale

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 7,373 shares of common stock on February 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Vanina de Verneuil, the EVP and General Counsel of Vir Biotechnology, sold 7,373 shares of common stock on February 26, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 5, 2024.
• The shares were sold at a weighted average price of $9.1418, with individual transaction prices ranging from $9.03 to $9.30.
• Following the transaction, de Verneuil directly owns 79,460 shares of Vir Biotechnology.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth above upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any inside information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The Rule 10b5-1 trading plan is a common tool used by executives to sell shares without raising concerns about insider trading, similar to practices at companies like Amgen or Regeneron.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates